JP2018501217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501217A5 JP2018501217A5 JP2017529388A JP2017529388A JP2018501217A5 JP 2018501217 A5 JP2018501217 A5 JP 2018501217A5 JP 2017529388 A JP2017529388 A JP 2017529388A JP 2017529388 A JP2017529388 A JP 2017529388A JP 2018501217 A5 JP2018501217 A5 JP 2018501217A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formulation
- pharmaceutical
- hcl
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086691P | 2014-12-02 | 2014-12-02 | |
| US62/086,691 | 2014-12-02 | ||
| US201562248071P | 2015-10-29 | 2015-10-29 | |
| US62/248,071 | 2015-10-29 | ||
| PCT/US2015/062985 WO2016089766A1 (en) | 2014-12-02 | 2015-11-30 | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020116157A Division JP7069253B2 (ja) | 2014-12-02 | 2020-07-06 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018501217A JP2018501217A (ja) | 2018-01-18 |
| JP2018501217A5 true JP2018501217A5 (enExample) | 2018-12-13 |
Family
ID=54848909
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529388A Pending JP2018501217A (ja) | 2014-12-02 | 2015-11-30 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| JP2020116157A Active JP7069253B2 (ja) | 2014-12-02 | 2020-07-06 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
| JP2022076280A Pending JP2022105159A (ja) | 2014-12-02 | 2022-05-02 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
| JP2024173051A Pending JP2025004090A (ja) | 2014-12-02 | 2024-10-02 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020116157A Active JP7069253B2 (ja) | 2014-12-02 | 2020-07-06 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
| JP2022076280A Pending JP2022105159A (ja) | 2014-12-02 | 2022-05-02 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
| JP2024173051A Pending JP2025004090A (ja) | 2014-12-02 | 2024-10-02 | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9458130B2 (enExample) |
| EP (2) | EP4063357B1 (enExample) |
| JP (4) | JP2018501217A (enExample) |
| KR (1) | KR102620681B1 (enExample) |
| CN (2) | CN111110677A (enExample) |
| AU (4) | AU2015355226B2 (enExample) |
| BR (1) | BR112017011555B1 (enExample) |
| CA (1) | CA2968977A1 (enExample) |
| CL (2) | CL2017001376A1 (enExample) |
| CO (1) | CO2017005498A2 (enExample) |
| DK (1) | DK3227273T3 (enExample) |
| EA (1) | EA201791226A1 (enExample) |
| ES (2) | ES3065087T3 (enExample) |
| HU (1) | HUE058212T2 (enExample) |
| IL (4) | IL280052B2 (enExample) |
| MX (1) | MX385586B (enExample) |
| MY (1) | MY185516A (enExample) |
| PE (1) | PE20171646A1 (enExample) |
| PH (1) | PH12017501007B1 (enExample) |
| PL (1) | PL3227273T3 (enExample) |
| PT (1) | PT3227273T (enExample) |
| SG (1) | SG11201704332YA (enExample) |
| TW (1) | TWI694069B (enExample) |
| UA (1) | UA122780C2 (enExample) |
| WO (1) | WO2016089766A1 (enExample) |
| ZA (1) | ZA201703481B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CN113694065A (zh) | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| CA3067031A1 (en) * | 2017-06-21 | 2018-12-27 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| CA3073957A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | Pharmaceutical compositions comprising sepiapterin and uses thereof |
| CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
| MA53437A (fr) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences Inc | Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| WO2020264486A1 (en) | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
| WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
| CN116251078B (zh) * | 2021-12-09 | 2025-12-19 | 河北以岭医药研究院有限公司 | 一种盐酸度洛西汀肠溶胶囊及其制备方法 |
| CA3243767A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ATE102482T1 (de) | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| KR927002347A (ko) | 1989-10-27 | 1992-09-03 | 레이몬드 지. 아너 | (n-프탈이미도알킬) 피페리딘 |
| FR2797643B1 (fr) | 1999-08-17 | 2003-06-06 | Rhodia Chimie Sa | Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures |
| IL151533A0 (en) * | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| DE60211494T2 (de) * | 2001-03-26 | 2006-10-12 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer |
| WO2006131711A1 (en) | 2005-06-06 | 2006-12-14 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2012012543A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals Inc. | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| DK2595484T3 (en) * | 2010-07-20 | 2018-01-22 | Minerva Neurosciences Inc | USE OF CYCLIC AMIDE DERIVATIVES FOR TREATMENT OF SLEEP DISORDERS |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20140010883A1 (en) * | 2011-03-17 | 2014-01-09 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CN113694065A (zh) | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| CA3067031A1 (en) | 2017-06-21 | 2018-12-27 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MA53437A (fr) | 2018-08-21 | 2021-06-30 | Minerva Neurosciences Inc | Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection |
-
2015
- 2015-11-30 JP JP2017529388A patent/JP2018501217A/ja active Pending
- 2015-11-30 PT PT158083147T patent/PT3227273T/pt unknown
- 2015-11-30 IL IL280052A patent/IL280052B2/en unknown
- 2015-11-30 WO PCT/US2015/062985 patent/WO2016089766A1/en not_active Ceased
- 2015-11-30 MY MYPI2017701998A patent/MY185516A/en unknown
- 2015-11-30 HU HUE15808314A patent/HUE058212T2/hu unknown
- 2015-11-30 ES ES22155504T patent/ES3065087T3/es active Active
- 2015-11-30 CN CN202010012498.9A patent/CN111110677A/zh active Pending
- 2015-11-30 UA UAA201706785A patent/UA122780C2/uk unknown
- 2015-11-30 PE PE2017000948A patent/PE20171646A1/es unknown
- 2015-11-30 TW TW104139904A patent/TWI694069B/zh active
- 2015-11-30 BR BR112017011555-7A patent/BR112017011555B1/pt active IP Right Grant
- 2015-11-30 IL IL313572A patent/IL313572A/en unknown
- 2015-11-30 KR KR1020177018088A patent/KR102620681B1/ko active Active
- 2015-11-30 ES ES15808314T patent/ES2910528T3/es active Active
- 2015-11-30 SG SG11201704332YA patent/SG11201704332YA/en unknown
- 2015-11-30 PL PL15808314T patent/PL3227273T3/pl unknown
- 2015-11-30 EP EP22155504.8A patent/EP4063357B1/en active Active
- 2015-11-30 CN CN201580065471.3A patent/CN107567444A/zh active Pending
- 2015-11-30 IL IL301320A patent/IL301320B2/en unknown
- 2015-11-30 EP EP15808314.7A patent/EP3227273B1/en active Active
- 2015-11-30 PH PH1/2017/501007A patent/PH12017501007B1/en unknown
- 2015-11-30 EA EA201791226A patent/EA201791226A1/ru unknown
- 2015-11-30 DK DK15808314.7T patent/DK3227273T3/da active
- 2015-11-30 MX MX2017007065A patent/MX385586B/es unknown
- 2015-11-30 CA CA2968977A patent/CA2968977A1/en active Pending
- 2015-11-30 US US14/954,264 patent/US9458130B2/en active Active
- 2015-11-30 AU AU2015355226A patent/AU2015355226B2/en active Active
-
2016
- 2016-09-28 US US15/278,421 patent/US9730920B2/en active Active
-
2017
- 2017-05-17 IL IL252347A patent/IL252347B/en active IP Right Grant
- 2017-05-19 ZA ZA2017/03481A patent/ZA201703481B/en unknown
- 2017-05-30 CL CL2017001376A patent/CL2017001376A1/es unknown
- 2017-05-31 CO CONC2017/0005498A patent/CO2017005498A2/es unknown
- 2017-07-17 US US15/651,065 patent/US10258614B2/en active Active
-
2019
- 2019-03-01 US US16/290,234 patent/US10799493B2/en active Active
-
2020
- 2020-06-26 AU AU2020204286A patent/AU2020204286B2/en active Active
- 2020-07-06 JP JP2020116157A patent/JP7069253B2/ja active Active
- 2020-09-11 US US17/017,816 patent/US20210228561A1/en not_active Abandoned
-
2021
- 2021-01-07 CL CL2021000044A patent/CL2021000044A1/es unknown
- 2021-09-10 AU AU2021229240A patent/AU2021229240B2/en active Active
-
2022
- 2022-05-02 JP JP2022076280A patent/JP2022105159A/ja active Pending
-
2023
- 2023-02-17 US US18/111,072 patent/US20230201184A1/en not_active Abandoned
- 2023-11-01 AU AU2023258386A patent/AU2023258386B2/en active Active
-
2024
- 2024-10-02 JP JP2024173051A patent/JP2025004090A/ja active Pending
- 2024-11-27 US US18/961,748 patent/US20250195494A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172531A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP5911969B2 (ja) | 心臓血管障害の治療方法 | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| JP2013522373A5 (enExample) | ||
| AU2012303683A1 (en) | Methods for treating cardiovascular disorders | |
| WO2013030725A1 (en) | Methods for treating cardiovascular disorders | |
| IL314873A (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| JP2015091822A5 (enExample) | ||
| JP2011098964A5 (enExample) | ||
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| JP2015510916A5 (enExample) | ||
| JP2016530238A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| JP2017533211A5 (enExample) | ||
| JP2017501235A5 (enExample) | ||
| KR20150075962A (ko) | 약물의 용출을 필요에 따라 용이하게 조절할 수 있는 모사프리드 구연산염 서방정 제제 | |
| JP2019507786A5 (enExample) | ||
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| KR20140001357A (ko) | 아세브로필린을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
| JP2013544795A5 (enExample) | ||
| EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии |